TDOC — Teladoc Health, Inc.

Is TDOC overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Health Information Services

Oversold As of October 3, 2026

Teladoc Health, Inc. (TDOC) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Health Information Services) last closed at $5.52. The rating moved from Strong Oversold to Oversold on October 2, 2026.

See all oversold Healthcare stocks →

AI analysis

Teladoc Health, Inc. (TDOC) remains a leader in virtual care with broad product coverage and partnership opportunities, but near-term performance is constrained by slower post‑pandemic demand growth, margin and cash‑flow pressures, and heightened sensitivity to payer reimbursement dynamics. The macro risk-off backdrop and cooling digital-health financing limit capital flexibility and valuation support. Mid-term upside depends on successful cost restructuring, stabilized utilization, and sustained payer contracts; downside scenarios include adverse reimbursement decisions, intensified competition from integrated insurers/providers, or the need for dilutive financing.

Key factors

  • Large, well-known telehealth platform with diversified service lines (virtual primary care, chronic care management, mental health) and long-standing provider relationships
  • Revenue growth has slowed vs. earlier pandemic-driven expansion; management focus on cost structure and margin improvement matters for near-term cash flow
  • Exposure to reimbursement and payer dynamics (Medicare/Medicare Advantage, commercial contracts) which drive utilization and revenue per visit
  • Competitive pressures from payers, large health systems and new entrants (insurers building in‑house virtual care, specialty digital-health offerings)
  • Macro risk-off environment for digital-health financing and M&A/IPO window cooling, limiting external capital options and valuation support
  • Partnerships, product bundling (chronic care, remote monitoring) and cross-sell potential provide medium-term revenue expansion levers if execution holds

Risks

  • Adverse reimbursement changes or Medicare negotiation outcomes that reduce per-member revenue or access to lucrative contracts
  • Intense competition from integrated payers/providers (Optum, UnitedHealthcare initiatives) and specialist vendors leading to pricing pressure and share loss
  • Continued cash burn or weak free-cash-flow requiring dilutive financing or asset sales in a risk-off capital market
  • Loss of utilization if in-person care rebounds or if consumers reduce discretionary virtual visits
  • Integration and execution risk from past acquisitions and complexity managing multiple product lines
  • Regulatory/privacy/security incidents that reduce trust or trigger fines and remediation costs

See today's live rating, score and targets

Members see the live hourly rating for TDOC — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.